Short Interest in Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Grows By 58.6%

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 52,800 shares, an increase of 58.6% from the February 28th total of 33,300 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 123,500 shares, the days-to-cover ratio is currently 0.4 days.

Shionogi & Co., Ltd. Trading Down 0.9 %

Shionogi & Co., Ltd. stock traded down $0.07 during trading hours on Friday, reaching $7.59. 44,701 shares of the company’s stock traded hands, compared to its average volume of 134,492. The firm has a market capitalization of $12.91 billion, a price-to-earnings ratio of 13.02, a PEG ratio of 2.37 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.01 and a current ratio of 7.64. Shionogi & Co., Ltd. has a fifty-two week low of $6.22 and a fifty-two week high of $8.59. The firm’s 50 day moving average is $7.41 and its 200-day moving average is $7.59.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its quarterly earnings data on Friday, January 31st. The company reported $0.16 earnings per share for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. On average, analysts predict that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.